Several studies have investigated whether diabetes and/or insulin (analogue) treatment increase breast cancer risk [5–10] or affect prognosis [11–18], because of their potential impact on tumor progression through e.g. the insulin-like growth receptor pathway [5,19]. This evidence concerns the gene INS and breast carcinoma.